Quarterly ResultAug 5, 2026, 04:11 PM
Editas Medicine Q2 Net Loss Narrows to $18.23M; Raises $116.9M
AI Summary
Editas Medicine reported a significant reduction in net loss for the second quarter of 2026, narrowing to $18.23 million from $53.24 million in the prior year. Collaboration and other research and development revenues saw a substantial increase to $11.89 million. The company bolstered its liquidity by raising $116.9 million in net proceeds from a public offering of common stock and warrants in May 2026, contributing to a total of $211.6 million in cash, cash equivalents, and marketable securities. Editas also suspended its at-the-market equity offering facility and updated its collaboration agreement with Bristol-Myers Squibb.
Key Highlights
- Net loss for Q2 2026 was $18.23 million, down from $53.24 million in Q2 2025.
- Collaboration and other R&D revenues for Q2 2026 increased to $11.89 million from $3.58 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $211.6 million as of June 30, 2026.
- Received net proceeds of $116.9 million from a public offering of common stock and warrants in May 2026.
- Total assets increased to $237.36 million at June 30, 2026, from $186.53 million at December 31, 2025.
- Total liabilities decreased to $132.08 million at June 30, 2026, from $159.25 million at December 31, 2025.
- Stockholders' equity rose to $105.28 million at June 30, 2026, from $27.29 million at December 31, 2025.
- Suspended and terminated the prospectus supplement for the at-the-market (ATM) facility in May 2026.
Price Impact
More from EDIT